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-Synuclein aggregation and accumulation in Lewy bodies
are implicated in progressive loss of dopaminergic neurons in
Parkinson disease and related disorders. In neurons, theHsp70s
and their Hsp40-like J-domain co-chaperones are the only
known components of chaperone network that can use ATP to
convert cytotoxic protein aggregates into harmless natively
refolded polypeptides.Herewe developed a protocol for prepar-
ing a homogeneous population of highly stable-sheet enriched
toroid-shaped -Syn oligomers with a diameter typical of toxic
pore-forming oligomers. These oligomers were partially resis-
tant to in vitro unfolding by the bacterial Hsp70 chaperone sys-
tem (DnaK, DnaJ, GrpE). Moreover, both bacterial and human
Hsp70/Hsp40 unfolding/refolding activities of model chaper-
one substrates were strongly inhibited by the oligomers but,
remarkably, not by unstructured-Synmonomers even in large
excess.Theoligomers acted as a specific competitive inhibitor of
the J-domain co-chaperones, indicating that J-domain co-chap-
erones may preferably bind to exposed bulky misfolded struc-
tures in misfolded proteins and, thus, complement Hsp70s that
bind to extended segments. Together, our findings suggest that
inhibition of theHsp70/Hsp40 chaperone system by-Syn olig-
omers may contribute to the disruption of protein homeostasis
in dopaminergic neurons, leading to apoptosis and tissue loss in
Parkinson disease and related neurodegenerative diseases.
A number of neurodegenerative disorders, such as Alzhei-
mer, amyotrophic lateral sclerosis, Huntington, prion enceph-
alopathy, and Parkinson diseases (PDs)2 are characterized by a
loss of neurons associated with protein misfolding and the
accumulation in and outside cells of stable protein aggregates
composed of specific proteins, such as tau tangles, amyloid-
plaques, -Syn fibrils, and Lewy bodies (1). Under ideal in vitro
conditions, such as low protein concentrations and low tem-
peratures, the primary amino acid sequence may suffice to dic-
tate the spontaneous folding of polypeptides into discrete
three-dimensional, active structures called the native state (2).
Yet in the crowded environment of the cell (for review, see Ref.
3) and especially under stress conditions, such as heat shock, de
novo synthesized or imported polypeptides andmutant or dam-
aged proteins may undergo transient unfolding, thereby expos-
ing hydrophobic segments that readily self-associate to form
stable non-functional high molecular weight, -sheet-en-
riched, oligomers and fibrillar assemblies, generally named
“aggregates” and amyloids (4, 5).
PD is characterized by the selective degeneration of dopam-
inergic neurons in the substantia nigra of human brain along-
side with the presence of cytoplasmic neuronal inclusions
called Lewy bodies (LBs). LBs are proteinaceous inclusions
mainly composed of aggregates and insoluble fibrillar -Syn
(6) associated with different members of the protein homeo-
stasis machinery. LBs and other types of -Syn inclusions are
also found in cases of dementia in some types of Alzheimer
disease, Down syndrome, and several other neurological dis-
eases, collectively denominated synucleinopathies (for review,
see Ref. 7).
-Syn is a 14.5-kDa protein mainly expressed in the central
and peripheral nervous systemof vertebrates, from torpedo fish
to humans (8). In humans, it is expressed mostly in presynaptic
terminals (9), astrocytic and oligodendroglial cells (10). Under
physiological conditions, native soluble-Syn is involved in the
differentiation of dopaminergic cells, where it functions as an
activity-dependent negative regulator of dopamine neurotrans-
mission (for review, see Ref. 11). Because in the purified state,
human-Syn is amonomer apparently devoid of stable second-
ary structures, it has been described as “natively” unfolded or
intrinsically unstructured (12, 13). Yet, in the membrane-rich
crowded environment of the cell, -Syn may become struc-
tured and upon binding to membranes is thought to adopt par-
tially an -helical conformation (14). During PD pathogenesis
or aging, loose -helical or natively unfolded -Syn monomers
may spontaneously convert, by a mechanism still unclear, into
highly stable -sheet-enriched oligomers, some of which pro-
tofibrils (15) that can ultimately formmore compact, protease-
resistant and apparently less toxic fibrils in LBs (for review, see
Ref. 16). Three specific point mutations in -Syn have been
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linked to autosomal dominant inherited forms of PD and cor-
relate with early onset of the disease (17–19). Interestingly, all
three also accelerate the in vitro oligomerization and fibril for-
mation of -Syn and promote the spontaneous formation of
toxic oligomers, including amyloid pores (20).
There is strong evidence that the soluble, low molecular
weight forms of -sheet-enriched oligomers are the primary
toxic species in the disease (21), whereas fibril formation is
already part of a detoxification mechanism whereby toxic olig-
omers become sequestered and, thus, incapacitated at partici-
pating in aberrant interactions withmembranes and other pro-
teins of the cell (for review, see Ref. 1). In solution and at high
concentrations (200 M), -Syn spontaneously forms annu-
lar pore-like structures (20, 21) that, when added externally to
the culture medium, can cause toxic ion leakage in neuroblas-
toma cells (22).
Here, we developed a reproducible protocol for preparing
and purifying a homogeneous population of highly stable
-sheet enriched, toroid-shaped -Syn oligomers with a diam-
eter typical of toxic protofibrils.We then compared the effect of
purified native monomeric -Syn to that of the purified olig-
omers on the in vitro ATP-dependent chaperone unfolding/
refolding activity of bacterial (DnaK, DnaJ or CbpA, GrpE) or
human (HSPA1A, DNAJA1) Hsp70/Hsp40 chaperones. We
found that-Syn oligomers can specifically inhibit the function
of the Hsp70/Hsp40 chaperone systems, suggesting that -Syn
oligomer-induced toxicity may also result from the specific
stalling of the cellular chaperonemachinery, leading to the col-
lapse of protein homeostasis and pathogenesis.
EXPERIMENTAL PROCEDURES
Purification and Characterization of Recombinant -Syn—
pT7 plasmid carrying the human wild-type (WT) -Syn gene
was expressed in BL21 (DE3) Escherichia coli cells. Cells were
grown in 1.2 liters of Lysogeny (Luria) Broth medium contain-
ing 100 mg/liter ampicillin at 37 °C with shaking. At A0.6, 0.2
mM isopropyl--D-thiogalactopyranoside was added, and cells
were further grown for 3 h. Centrifuged cells were sonicated in
buffer A (50 mM Tris, pH 8.0, 50 mM KCl, 5 mM Mg(Ac)2, 0.1%
Na azide), 0.2 mg/ml lysozyme, and the protease inhibitor mix-
ture from Sigma (catalog no. P8465). After 15 min of centrifu-
gation at 6000 rpm, the supernatant was heated at 73 °C for 4.5
min. After a second 15-min centrifugation at 10,000 rpm, the
supernatant was precipitated in 40% (NH4)2SO4 and incubated
overnight at 4 °C. After a 15-min centrifugation at 6000 rpm,
the pellet was then resuspended in Buffer A, filtered through a
0.2-m membrane, and loaded on a Superose 6 gel filtration
column (Amersham Biosciences). Proteins were eluted in
buffer A at a flow rate of 0.5 ml/min. For each eluted peak,
fractions were pooled and concentrated by ultrafiltration in a
100-kDa cut-offmembrane (Sartorius 13269E) and analyzed on
a 15% SDS-PAGE or on a 5.5% native PAGE and stained with
Coomassie Blue. The total protein concentration was deter-
mined at 560 nm with the bicinchoninic acid assay (BCA)
(Sigma) using bovine serum albumin as a standard and then
stored in buffer A supplemented with 20% glycerol at80 °C.
Immunoblotting—Samples were separated on a 7.5% native
PAGE or on a 12% SDS-PAGE (Fig. 1) and transferred by elec-
troblotting to a nitrocellulose membrane (Bio-Rad) using
standard protocols. Membranes were blocked in 1% skimmed
milk and incubated overnight at 4 °C with a rabbit anti--Syn
polyclonal antibody (Stressgen, Ann Arbor, MI, catalog no.
905-565) (1/1000, v/v) and then incubated with a HRP-labeled
goat anti-rabbit antibody (Bio-Rad, catalog no. 170-5046)
(1/15000, v/v). Immune complexes were visualized using the
chemiluminescent ImmunstarTMKit (Bio-Rad) according to
the manufacturer’s instructions.
Proteins—DnaK, DnaJ, and CbpA were purified according to
Gur et al. (24); ClpB was purified according to Woo et al. (25).
His-tagged Luciferase was expressed from the pT7lucC-His
plasmid fromA. S. Spirin (TheProteinResearch Institute,Mos-
cowRegion, Russia) andpurified according to Svetlov et al. (26).
GrpE was a gift from H.-J. Scho¨nfeld, F. Hoffmann-La Roche,
Basel, Switzerland. Glucose-6-phosphate Dehydrogenase
(G6PDH) from Leuconostoc mesenteroides and BSA were from
Sigma. Heat denaturation of the G6PDH was as described in
Ben-Zvi et al. (27). Cold inactivation of His-tagged Luciferase
was achieved by four consecutive cycles of freezing in liquid
nitrogen and slow thawing at 4 °C (62).
Atomic Force Microscopy—10 l of -Syn monomers or oli-
gomers (1 M each, expressed in protomers) in buffer (50 mM
Tris, 50 mM KCl, 10 mM MgCl2, pH 7.5) were deposited onto
freshly cleaved mica at room temperature. After 1 min, the
sample was gently rinsed with 1ml of nanopure H2O and dried.
Samples were imaged using a Nanoscope III (Digital Instru-
ment, Santa Barbara, CA) in the tapping mode. The probes
were NSC35 (NT-MDT, Troisk, Russia).
Reactivation of Heat-preaggregated G6PDH by Chaperones—
Heat-preaggregated G6PDHwas refolded by the DnaK chaper-
one system as described in Ben-Zvi et al. (27) with the following
modifications; 0.75 M heat-aggregated G6PDH (final concen-
tration) was reactivated in the presence of 5 M DnaK, 5 M
DnaJ, 0.5 M GrpE (the full DnaK chaperone system) or 5 M
HSPA1A and 5 M DNAJA1 (the minimal human Hsp70/40
system), and 4 mM ATP. G6PDH activity was measured at dif-
ferent times of chaperone-mediated refolding reaction at 30 °C.
Luciferase Assays—Luciferase activity was measured as de-
scribed previously (26) using aVictor Light 1420 Luminescence
Counter from PerkinElmer Life Sciences.
Inhibition of G6PDH Reactivation by -Syn Species—Ali-
quots from each eluted fraction resulting from the gel filtration
chromatographywere diluted to a final concentration of 2.2M
-Syn and added to 0.75Mheat-inactivatedG6PDHand incu-
bated in the presence of the full DnaK/DnaJ/GrpE bacterial
systemor theminimalHsp70/Hsp40 human system at 30 °C for
1 h. G6PDH activity was measured at different times of chap-
erone-mediated refolding reaction.
Thioflavin T Fluorescence Assays—The -sheet content of
G6PDH and -Syn were evaluated by measuring the fluores-
cence in a luminescence spectrometer, PerkinElmer Life Sci-
ences LS 55 (excitation, 446 nm; emission, 480 nm), in a 500-l
cuvette containing 10 M thioflavin T (Th-T) (final concentra-
tion) in the refolding buffer: 100 mM Tris-HCl, pH 7.5, 100 mM
KCl, 10mMMgAc, 10mMDTT, 4mMATP, 4mMPEP, and 0.02
mg/ml PK.
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RESULTS
To address the possible effects of unstructured -Synmono-
mers and structured oligomers on the in vitro activity of a typ-
ical Hsp70/Hsp40/NEF chaperone system (here, the E. coli
DnaK/DnaJ/GrpE chaperone machinery), we first designed a
protocol to purify a distinct population of stable -Syn olig-
omers with reproducible characteristics. Immunoblots from
SDS gels of soluble extracts from E. coli cells overexpressing
plasmid-encoded human -Syn revealed a predominant frac-
tion of SDS-soluble 14.5-kDa -Synmonomers (Fig. 1A, lane 1,
I) and aminor fraction of SDS-resistant oligomers: somedimers
(Fig. 1A, lane 1, II), highmolecular weight species thatmigrated
as 10–14-mers (Fig. 1A, lane 1, III), and very large insoluble
oligomers that did not enter the resolution gel (Fig. 1A, lane 1,
IV). To deplete this last insoluble fraction of very large SDS-
resistant oligomers (fraction IV), the extractwas heat-treated at
73 °C for 4.5min and centrifuged (14,000 rpm, 15min) (Fig. 1A,
lane 2). After ammonium sulfate precipitation, we obtained a
much reduced fraction, albeit of 95% pure -Syn, that was
devoid of large insoluble species, composed of fully soluble,
discrete oligomers that resolved on native gel mainly as 10–14
mers (140–200 kDa) as well as some dimers and monomers
(Fig. 1B, lane 3).
To better understand the relative size distribution of mono-
meric and oligomeric -Syn complexes, this soluble fraction
was further separated by gel filtration (Fig. 2A, blue line). As
expected from the native gel (Fig. 1B), we observed two broad
peaks; one corresponding to soluble high molecular weight
(Mr) -Syn oligomers ranging from 102 to 103 kDa (7.5–11 ml)
with a very high specific affinity for the amyloid specific dye,
Th-T, and a second that was resolved at the expected position
of the 14.5-kDa -Syn monomer (15–18 ml) with a very low
specific affinity for Th-T (Fig. 2A, dark line). SDS and native gel
electrophoresis confirmed that this lowMr fraction contained a
uniform population of SDS-soluble 14.5-kDamonomers whose
low affinity for Th-T is indicative of a lack of-sheet structures,
in agreement with the intrinsically unfolded state that is pre-
dominantly observed in the case of -Syn monomers in vitro
(13). In contrast, SDS and native gel electrophoresis confirmed
that the highMr, -sheet-enriched fraction from the 7.5–11ml
peak was partially SDS-resistant (Fig. 2B) and formed on the
native gel a remarkably discrete soluble -Syn oligomer whose
high stability was reflected by its ability to withstand extensive
dilutions during gel filtration and native gel electrophoresis
(Fig. 2C).
The discrete nature of this stable highMr, yet soluble -Syn
oligomer was confirmed by atomic force microscopy (Fig. 2,
D–G); whereas the low Mr fraction contained mostly -Syn
monomers, undetectable at this low resolution (Fig. 2D), the
high Mr fraction showed a dense, remarkably homogeneous
population of globular, mildly flattened oligomers (Fig. 2E),
with a narrow size distribution (average diameter of 21 nm 3
nm) (Fig. 2G). The tapping procedure revealed a weaker region
at the center of the particles, suggesting a less dense interior or
a pore-like toroid (Fig. 2F) indistinguishable in size and shape
from previously described toxic pore-forming -Syn oligomers
(20).
This protocol of production of stable -Syn oligomers was
highly reproducible. Yet, depending on the batches, -Syn oli-
gomers bound about 20 times more Th-T than monomeric
-Syn and about 8 times more than heat-aggregated G6PDH
(Fig. 3A). G6PDH is a heat-generated misfolded protein sub-
strate that is commonly used to test the unfolding/refolding
activity of molecular chaperones (5, 27). The high stability of
the-sheet structures in the-Syn oligomerswas confirmed by
their relative high resistance to prolonged (48 h) incubations
after extensive dilutions; whereas prolonged incubations of
heat-aggregated G6PDH caused a 33% loss of Th-T binding
(Fig. 3B), only 8% loss of Th-T binding was observed in the
case of -Syn oligomers under identical conditions (Fig. 3C).
We next addressed the biochemical properties of -Syn olig-
omers as a possible substrate of the full E. coli Hsp70 chaper-
one machinery. Confirming earlier observations (27), in the
presence of DnaK, DnaJ, GrpE, and ATP, heat-preaggregated
G6PDH lost 25% of its Th-T binding structures within 50 min
(Fig. 4A, open squares) and correspondingly formed 25% of
natively refoldedG6PDHenzyme (Fig. 4A, filled circles). In con-
trast, the-Syn oligomers lost less than 10%of their Th-T bind-
ing structures (Fig. 4A, filled squares), indicating that although
interacting with the aggregates, the chaperones are less effec-
tive at unfolding the misfolded -sheets structures in -Syn
oligomers than in heat-aggregated G6PDH substrate. Remark-
ably, immunoblots of native gels confirmed that the Hsp70
chaperone machinery can convert a significant fraction of the
stable -Syn oligomers into monomers in an ATP-depen-
dent manner (Fig. 4B). This indicates that the chaperone
machinery, although capable of interacting and causing the
partial disassociation of the oligomers, are poorly effective at
fully unfolding stably misfolded -sheets structures into
unstructured polypeptide segments.
Thus, we next addressed the possibility that the oligomers
may stall the Hsp70/40 chaperone machinery. The in vitro
chaperone-mediated ATP-dependent reactivation of G6PDH
was tested in the presence of increasing amounts ofmonomeric
FIGURE 1. The initial stages in the purification of recombinant
-synuclein protofibrils. Shown is an immunoblot with an anti--synuclein
antibody from a SDS gel (A) or a native gel (B) of cell extracts from BL21 E. coli
cells expressing WT human -synuclein. Lane 1, soluble initial crude extract.
Lane 2, soluble extract after heat treatment. Lane 3, resolubilized ammonium
sulfate pellet from the heat-treated soluble extract in lane 2. Numbers, esti-
mated molecular masses from the SDS gel in kDa. Roman numbers with
arrows: I, monomers; II, dimers; III, soluble oligomers; IV, large oligomers that
do not enter the resolution gel.
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FIGURE 2. Characterization of recombinant human -synuclein (AS). A, shown is size exclusion chromatography of recombinant -synuclein from the
resolubilized amonium sulfate pellet of the heat-treated crude extract shown in lane 3 of Fig. 1, A and B. Elution profile from the Superose 6 column shows the
protein concentration profile according to the absorbance at 280 nm (blue circles) and the Th-T fluorescence profile (black circles). Above the inset, Coomassie
stain of the correspondingeluted fractions after separationon12%SDS-PAGE is shown.B andC, two fractionswerepooled from15–18ml asmonomeric AS and
from 7.5–11ml as oligomeric AS, concentrated, and further separated by SDS-PAGE (B) or native-PAGE (C) and Coomassie-stained. Standardmolecular masses
(M) in kDa are indicated for the SDS-gel. D–F, shown are atomic force microscopy morphological studies of AS monomers and AS oligomers, as in B and C.
Atomic force microscopy images (1 m 1 m) of AS monomers (D) and AS oligomers (E) are shown. At higher magnitude, AS oligomers present a globular
flattened-shape structure (F). G, shown is cumulative function of the diameter distribution of the AS oligomers with a mean size of 21.1 nm and a S.D. s 2.4
nm. Inset, shown is s histogram of the distribution superimposed with a Gaussian (mean 21.1 nm, s 2.4 nm).
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or oligomeric -Syn (Fig. 5A). We found that the refolding rate
of heat-pre-aggregated G6PDH by an excess of chaperones (5.0
M DnaK, 1 M DnaJ, and 0.5 M GrpE) was strongly inhibited
by -Syn oligomers but not by the monomers. Half-inhibition
of the chaperone reaction was observed in the presence of 2M
-Syn oligomers (expressed in protomers) (Fig. 5B). Remark-
ably, up to a 10-fold molar excess of monomeric -Syn did not
inhibit and was even slightly beneficial to the chaperone reac-
tion (Fig. 5A, open circles). Chaperone inhibitionwas specific to
-Syn oligomers and not to other types of protein aggregates, as
equimolar amounts of heat-aggregatedMDH or of cold-inacti-
vated luciferase did not compete with the chaperone-mediated
reactivation of heat-denatured G6PDH (supplemental Fig. S1).
Moreover, the oligomers inhibited the chaperone-mediated
refolding of cold-inactivated Luciferase to the same extent as
they did in the case of heat-denatured G6PDH (supplemental
Fig. S2), indicating that inhibition is not caused by the compe-
tition between the different substrates for a limited amount of
chaperones but rather by a non-competitive actionmediated by
a specific interaction of the oligomers with a component of the
chaperone system. This specific chaperone inhibitory effect
was further tested on different-Syn oligomers with increasing
apparent molecular masses (and/or shapes, as elongated pro-
teins may elute with larger than real
apparent molecular masses) ob-
tained by gel filtration fractionation.
Remarkably, the size/shape-depen-
dent profile of the specific chaper-
one inhibitory activity (Fig. 5C)
matched that of the specific Th-T
binding (Figs. 2A and 5C), suggest-
ing a strong correlation between the
-sheet or amyloid-like content of
the -Syn oligomers and their abil-
ity to inhibit the chaperone activity.
The specific in vitro inhibitory
effect of the -Syn oligomers was
confirmed with HSPA1A and
DNAJA1, which represent a central
hub of the stress-induced chaper-
one network and are among the
most strongly expressed Hsp70
chaperone and Hsp40 co-chaper-
ones of the cytoplasm of human
cells, includingPDneurons prone to
-Syn aggregation (61). We found
that, similar to E. coli Dnak/DnaJ/
GrpE chaperones, -Syn oligomers,
but not monomers, strongly inhib-
ited the human HSPA1A/DNAJA1
chaperone machinery (supplemen-
tal Fig. S3A). Moreover, in the pres-
ence of 1.5 M DNAJA1, inhibition
was half, and in the presence of 3M
DNAJA1, inhibition was fully allevi-
ated. This confirms that, as with
bacterial chaperones, the inhibition
of the human chaperone system by
the -Syn oligomers, but not by themonomers, is also predom-
inantly caused by the incapacitation of theHsp40 co-chaperone
(supplemental Fig. S3B).
Both chaperone and co-chaperone can bind to unfolded or
misfolded proteins, albeit in differentmanners (28).Whereas in
its ADP-liganded and substrate-bound state, DnaKmay tightly
bind only to protruding unfolded hydrophobic polypeptide seg-
ments by tightly enclosing them, DnaJ may directly bind with
much less steric limitations to bulky hydrophobic surfaces on
misfolded structures on the substrate (28–30). Therefore, we
next considered the possibility that -sheet-enriched olig-
omers expose binding sites with a particular affinity for DnaJ,
thereby potentially stalling the chaperone reaction. This was
addressed by measuring the rates of ATP- and chaperone-me-
diated refolding without or with a fixed amount of oligomeric
-Syn in the presence of increasing concentrations of DnaK
(Fig. 6A) or of DnaJ (or the DnaJ-like co-chaperone CbpA) (Fig.
6, B and C) or of chaperone substrate (Fig. 6D). The half inhib-
itory effect (IC50), which was observed at 5 M DnaK, was not
alleviated by higher DnaK concentrations of up to 13 M (Fig.
6A), suggesting that inhibition is not because DnaK becomes
sequestered by the oligomers. As expected, excess GrpE did not
alleviate inhibition (data not shown), consistent with the fact
FIGURE 3. AS oligomers are stable and -sheet-enriched. A, the specific -sheet content of various protein
forms is shown. The relative Th-T fluorescence by a constant amount (1 M, expressed in protomers) of AS
oligomers was compared with AS monomers (black bars) to heat pre-aggregated and to native G6PDH (white
bars). B and C, shown is an estimation of the relative stability of various oligomers. The relative Th-T fluores-
cence (normalized to 1 M, expressed in protomers) of heat-pre-aggregated G6PDH (B) and AS oligomers (C)
was measured either immediately after dilutions from 1 to 0.1 M (open circles) or 48 h after dilutions (filled
symbols). AU, absorbance units.
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that GrpE is a mere nucleotide exchange factor that exclusively
interacts with DnaK. In contrast, increasing concentrations of
the J-domain co-chaperones were found to gradually alleviate
chaperone inhibition by oligomers (Fig. 6, B and C); inhibition
was strongly diminished above 2.5 M DnaJ and was negligible
at 5 M DnaJ (Fig. 6B). This was confirmed using CbpA, which
can substitute for DnaJ in our type of in vitro DnaK-mediated
protein disaggregation assays (24); the inhibition, which was
initially set to 50%, remained so below 1 M CbpA. The inhibi-
tion gradually decreased above 1 M CbpA and in the presence
of 5 M CbpA was reduced to 10% (Fig. 6C). This suggests that
-Syn oligomers may inhibit the chaperone reaction by way of
specifically sequestering the J-domain co-chaperones.
Because the same quality of G6PDH aggregates cannot be
obtained when they have been heat-denatured at different con-
centrations (31), we chose to use freeze-inactivated luciferase,
which shows no differences of chaperone reactivity once inac-
tivated at different concentrations (62) to test the effect of
increasing concentrations of a chaperone substrate. Here again,
the same amount of oligomers, which inhibited by half the
chaperone-mediated refolding of 125 nM luciferase, kept inhib-
iting by more than half the refolding of five times more lucifer-
FIGURE 4. AS oligomers are partially resistant to the Hsp70 chaperone
machinery. A, AS oligomers are more resistant to the unfolding chaperones
than G6PDH aggregates. Time-dependent loss of Th-T fluorescence (squares)
of 1 M heat pre-aggregated G6PDH (open squares) or 1 M (protomers) AS
oligomers (filled squares) in the presence of 5 M DnaK, 0.75 M DnaJ, and 1
M GrpE (KJE) and ATP and the corresponding time-dependent reactivation
of native G6PDH (filled circles) is shown. B, AS oligomers are partially dissoci-
ated by the ATP-fueled DnaK/DnaJ/GrpE chaperone system. AS oligomers
were incubated as in A but for 3 h at 30 °C with or without ATP and chaper-
ones, as specified. Samples were separated on native gel, and -synuclein
was detected by Western blot analysis as in Fig. 1.
FIGURE 5. AS oligomers inhibit the unfolding/refolding activity of the
Hsp70 chaperone system. A, time-dependent reactivation of heat-pre-ag-
gregated G6PDH by the full DnaK chaperone system is shown. The heat pre-
aggregated G6PDH (0,75 M) was first incubated with increasing concentra-
tions of AS oligomers (0- 20 M protomers) (filled symbols) or 20 M AS
monomers (open symbols, asterisk) and then incubatedwith 5MDnaK, 1M
DnaJ, 0.5 M GrpE, and ATP. B, optimal G6PDH refolding rates from A as a
function of increasing concentrations of AS monomers (open triangles) or
oligomers (filled triangles) are shown. C, the specific chaperone inhibitory
activity profile (open circles) compared with the Th-T binding profile (filled
circles) of AS species in the different fractions from the size exclusion chroma-
tography in Fig. 2B is shown.
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ase (650 nM) substrate (Fig. 6D). Thus, inhibition cannot be
attributed to the sequestering of the chaperone substrate by
-Syn oligomers.
DnaJ and -Syn being devoid of Trp residues, we could fol-
low the changes in the steady-state intrinsic fluorescence of the
unique Trp residue, which is in the nucleotide binding domain
of DnaK, in the presence of ATP and increasing amounts of
monomeric or oligomeric-Synwith orwithoutDnaJ. Fluores-
cence changes (supplemental Fig. S4) showed that in the
absence of DnaJ, DnaK had the same low apparent affinity for
monomeric -Syn as for oligomeric -Syn. In contrast, in the
presence of DnaJ, increasing amounts of oligomeric -Syn
caused a dramatic change in the DnaK fluorescence, whereas
increasing amounts of monomeric -Syn caused similar minor
fluorescence changes, as without DnaJ. This confirms that it is
the DnaJ co-chaperone rather than the DnaK chaperone that is
able to specifically distinguish between oligomeric and mono-
meric -Syn. Moreover, DnaJ acts as if it instructed DnaK to
interact with the oligomers and specifically act upon them as a
disaggregating/unfolding chaperone.
DISCUSSION
Recombinant -Syn Oligomers Recapitulate Biochemical
Properties of Oligomers from PD Tissues—The physiological
non-toxic species of -Syn is presumably a soluble monomer
that in healthy neurons may loosely bind to membranes as
amphiphilic -helices (14). In the
purified state the full-length -Syn
polypeptide is found in a so-called
natively unfolded or unstructured
state, apparently devoid of second-
ary structures. At high concentra-
tions, -sheet-enriched oligomers
may spontaneously form by a yet
unclear mechanism and undergo
subsequent growth and/or self-as-
sembly to form the mature fibrils
found in the Lewy bodies of PD
brains (32). Soluble oligomers, typi-
cally composed of about 12–24 sub-
units, were isolated from the cere-
bral cortex of PD and dementia with
LBs patients and from -Syn-
transgenic mesencephalic neuronal
(MES) cells and mouse brains (33).
Because oligomers have a higher
surface/volume ratio as compared
with large fibrils and amyloids, they
can be very toxic, and their appari-
tion in cells correlates with a general
failure of the protein homeostasis
(proteostasis) machinery, the onset
of apoptosis, tissue loss, and neuro-
degeneration (34, 35).
Both artificially formed and in
vivo formed -Syn oligomers are
partially resistant to detergents such
as Triton and SDS (36) and have a
typical high affinity for the amyloid-specific dyes likeCongo red
or Th-T (37). Upon reconstitution in synthetic membranes,
they can spontaneously form discrete spheroid pore-like struc-
tures that cause ion leakage (38). -Syn oligomers have been
previously isolated from cold-induced dissociation of amyloid
fibrils (39). Here, we described a protocol to isolate recombi-
nant human -Syn oligomers that recapitulate a number of
important properties of the toxic -Syn oligomers found in PD
neuronal tissues; they were very stable soluble oligomeric spe-
cies that were partially resistant to SDS. They could withstand
extensive dilutions and native gel electrophoresis and bound
much more Th-T (here about 20 times) than the monomeric
form. Moreover, the -Syn oligomers were a remarkably uni-
form population of discrete spheroid-like flattened structures
of the same diameter as previously described for the toxic spe-
cies shown to spontaneously form pores in artificial mem-
branes and cause ion leakage in cell cultures.
Yet, in contrast to classic protofibrils, we found that these
oligomers remained ineffective as seeds of spontaneous -Syn
fibril formation in vitro (supplemental Fig. S5). This suggests
that our specific -Syn oligomers are off-fibrillation pathway
species whose negative effects on the chaperone network and
possibly on the cell cannot be neutralized by the spontaneous or
aggresome-mediated formation of less toxic larger fibrils and
amyloids.
FIGURE 6. AS protofibrils interact with J-domain chaperones. The reactivation of heat-pre-aggregated
G6PDH was performed under the same conditions as in Fig. 4A with constant GrpE (0.5 M) and increasing
DnaK, DnaJ, or CbpA or luciferase substrate concentrations without (open circles) or with AS oligomers (4 M
protomers) (filled circles). A, shown are optimal rates of G6PDH reactivation by constant (1 M) DnaJ and
increasingDnaKconcentrations.B, shownareoptimal ratesofG6PDHreactivationbyconstant (5M)DnaKand
increasing DnaJ concentrations. C, procedures are as in B but with increasing CbpA concentrations instead of
DnaJ.D, shown is optimal rates of luciferase reactivation by constant (0.8M) DnaK, (0.4M) DnaJ, and (0.8M)
GrpE and increasing concentrations of inactive luciferase substrate without (open circles) or with AS oligomers
(2 M protomers) (filled circles).
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The -Syn Oligomers Feebly but Effectively Interact with the
Hsp70 Chaperone Machinery—Although Th-T fluorescence
showed that, as compared with denatured G6PDH or lucifer-
ase, the -Syn oligomers were relatively resistant,Western blot
analysis of native gels revealed that oligomers were relatively
efficiently disaggregated by the bacterial ATP-dependent
Hsp70 chaperone machinery. This is consistent with earlier
finding (40) showing that human Hsp70 can efficiently inhibit
-Syn fibril formation in vitro and further suggests that partial
ATP-fuelled, chaperone-mediated unfolding can lead to the
partial disaggregation of -Syn oligomers. It should be noted,
however, that incomplete chaperone-mediated unfolding of
more compact and, therefore, less toxic aggregates could lead to
a transient increase of protein toxicitywhenmore active species
are formed but are not further converted into nontoxic mono-
mers. The concomitant binding of more than one Hsp70 mol-
ecule to the same misfolded polypeptide has been shown to be
essential for the effective cooperative unfolding action of the
chaperone on relatively resistant protein aggregates such as
heat-denaturedG6PDH species (27, 41). According to the algo-
rithm of Ru¨diger et al. (29), the -Syn sequence has only one
good potential Hsp70 binding site (instead of the three-four
sites expected on an average polypeptide of the same size). The
lack of another chaperone binding site would strongly limit the
ability of the single chaperone molecule to efficiently pull and
unfold the stable -sheets and could explain the apparent
resistance ofmisfolded-Syn conformers to the protein quality
control machineries in neurons affected by PD (for review, see
Ref. 4).
-Syn Oligomers Inhibit the Unfolding Activity of the Hsp70/
40 System—Consistent with the observed co-localization of
humanHsp40 proteins (andHsp70) with -Syn in Lewy Bodies
(34), our -Syn oligomers behaved in vitro as a competitive
inhibitor of the human and bacterial (E. coli) Hsp70/40 chaper-
one machineries by interacting with J-domain co-chaperones.
Noticeably, we found that DnaJ preincubated either with-Syn
monomers or with oligomers did not show differences of elu-
tion profiles on gel filtration and, moreover, that DnaJ did not
co-immunoprecipitate with -Syn oligomers better than with
monomers (data not shown). We conclude that the specific
strong inhibitory effect that is exerted by the -Syn oligomers
on the J-domain co-chaperones must be mediated by rather
weak interactions. This is not entirely surprising given that a
very ubiquitous “generalist” chaperone, such as Hsp70/Hsp40
could hardly afford having very strong affinities for hundreds of
different substrate proteins in various misfolded and aggre-
gated states in the same cell.
We found that tryptophan fluorescence independently sup-
ported the evidence from the chaperone assays and confirmed
that the J-domain co-chaperone is the primary component of
the Hsp70 chaperone system that can specifically distinguish
between the oligomeric and themonomeric form of -Syn and,
moreover, direct Hsp70 to interact with -Syn oligomers in a
limited attempt to disaggregate them.
The binding of de novo-forming oligomers to Hsp40
co-chaperones would partially sequester and, therefore, neu-
tralize the whole Hsp70/Hsp40 chaperone system, adding to
the direct deleterious effects of oligomers on membrane integ-
rity (38) and the indirect effects on the stability of other labile
andmutant proteins in the cell, as observed in the case of polyQ
aggregates in thermo-sensitive mutants of Caenorhabditis
elegans (42). In addition, because Hsp70/Hsp40 activity can
repress IkB and, therefore, repress NF-B-mediated apoptosis
(43), the blockage of Hsp70/Hsp40 by -Syn oligomers could
promote neuroinflammation, cell death, and tissue loss in PD.
Moreover, the toxicity of -Syn oligomers may not only
result from the inhibition of the Hsp70/40 chaperone machin-
ery.-Syn oligomers have also been shown to strongly inhibit in
vitro protein degradation mediated by the 26 S proteasome
(44). Likewise, PC12 cells expressing the pathogenic A53T
and/or A30P -Syn diseases-associated mutants showed an
altered lysosomal activity as compared with WT -Syn (45).
This fits in vivo observations of altered proteasomal and/or
lysosomal pathways in dopamine neurons of the substantia
nigra from PD patients (35). Together, this suggests that -Syn
oligomers may impair their own degradation along with that of
other damaged proteins in the cell, leading to a vicious cycle of
proteostasis imbalance, causing cell death (for review, see
Ref. 46).
The Hsp70/Hsp40 Is the Main Chaperone That Can Unfold
Toxic Protein Conformers in Neurons—Previous studies have
demonstrated the positive effect of molecular chaperones,
more particularly of the Hsp70/40 chaperone system, on the
cytotoxicity of -Syn oligomers. Hsp70 overexpression in flies
expressing -Syn prevents dopaminergic neuronal loss caused
by -Syn oligomers. It also reduces -Syn oligomerization both
in mice and in H4 cells expressing -Syn. In the mouse model
Hsp70 overexpression leads to a significant reduction both in
high molecular weight and detergent-insoluble -Syn species
(47). Moreover, purified Hsp70 effectively inhibits -Syn fibril
formation in vitro and suppresses the permeabilization of syn-
thetic vesicles induced by prefibrillar -Syn (40). Chaperones
other than Hsp70/Hsp40 may also contribute to the reduction
of toxic oligomers in the cytoplasm of mammalian cells; the
expression of Hsp27 or of the yeast Hsp104 can reduce toxicity
associated with -Syn oligomers in human H4 neuroglioma
cells or rat models of PD, respectively (48, 49). However, the
contribution of sHSPs is expected to be limited to the passive
prevention of protein aggregation as, unlikeHsp70/Hsp40, they
cannot use the energy of ATP hydrolysis to unfold misfolded
proteins. It can, however, stabilize and deliver misfolded pro-
teins to the Hsp70/Hsp40 chaperone system (50).
True functional homologues of ClpB acting together with
Hsp70/Hsp40/NEF in the disaggregation of large compact
aggregates (51) have been identified only in bacteria in the
organelles and the cytoplasm of plants, yeast, and fungi (for
review, see Ref. 5). In animal cells, among themany cytoplasmic
AAA proteinswith conservedWalkermotives, none has been
convincingly shown thus far to function as true ClpB/Hsp104
homologues. Our immunoblot analysis showed that, unlike
with a classic heat-aggregated chaperone substrate, -Syn olig-
omers remained resistant to the unfolding action of ClpB,
which remained unable to improve the limited disaggregating
activity ofDnaK/DnaJ/GrpE alone (data not shown).Hence, the
Hsp70/40/NEF remains thus the only known chaperone
machinery in the cytoplasmofmammalian cells that canuse the
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energy of ATP hydrolysis to unfold toxic misfolded protein
conformers, such as -Syn oligomers, into non-toxic natively
refoldable or protease-degradable species (5, 27).
Recruiting Hsp70/Hsp40/NEF to Reduce PD Is a Promising
Therapeutic Approach—An age-dependent progressive failure
of the protein clearance machinery, including the Hsp70/
Hsp40 chaperone system, has been shown in aging organisms
(for review, see Ref. 52). Interestingly, in agreement with our
finding that J-domain co-chaperones play a central role in
aggregate recognition and processing, a systematic screen in
human cell cultures expressing disease-associated polyglu-
tamine proteins (polyQ) revealed that two human DnaJ homo-
logues, DNAJB6b and DNAJB8, are effective suppressors of
polyQ aggregation and toxicity (53). This suggests new avenues
of therapeutic approaches using chaperone-inducing drugs,
such as Hsp90 inhibitors (54) or non-steroidal anti-inflamma-
tory drugs (55). Alternatively, vectors could mediate the spe-
cific expression of particular effective J-domain co-chaperones
in aging or diseased neurons, thus, targeting more effectively
the unfoldase activity of the cytoplasmic Hsp70/Hsp40s to the
cytotoxic -Syn oligomers in PD.
Mechanistic Implications; J-domain Co-chaperones May
Preferably Bind Misfolded Structures—Although the native
unstructured monomeric form of human -Syn apparently
optimally exposes a typical high affinity binding motive,
32KTKEGVLYVGSKTR45, for the potential binding and lock-
ing ofHsp70 (29) (see supplemental Fig. S6), we found that even
in large molar excess, it did not inhibit the ATP- and DnaK/
DnaJ/GrpE-mediated unfolding/refolding reaction of classic
amenable chaperone substrates. This is consistent with NMR
and gel filtration studies that showno interaction ofHsp70with
monomeric -Syn (56, 57). Our work further shows that DnaJ
too has no apparent affinity for the unstructured monomeric
form of -Syn. In contrast, we found that the three J-domain
co-chaperones, DnaJ, CbpA, and DNAJA1, have an apparent
specific affinity for the structured oligomeric form of the same
protein. This is consistentwith earlier findings showing that the
yeast Sis1 and Ydj1 Hsp40s co-chaperones have a stronger
affinity for Sup35 prionogenic oligomers than for the soluble
monomers (58). Thus, unlike Hsp70, which in the ADP-ligan-
ded state may only “lock” around extended loops extruding
from the aggregate, J-domain co-chaperones may directly bind
surfaces of bulky misfolded structures made of hydrophobic
residues joined in trans, which are otherwise individually scat-
tered in the primary sequence. This could explain why in the
unfolded-Synmonomer, for lack of a DnaJ binding site, DnaK
lacks the ability to lock onto the DnaK binding site and more-
over could justify why J-domain co-chaperones do not neces-
sarily compete withHsp70 for substrate binding andwhy chap-
erone and co-chaperone best collaborate when they are bound
alongside rather than instead of each other on the same native
(59) or unfolded polypeptide substrate (23, 28). Moreover, this
would explain for the first time how, subsequent to their initial
binding to the substrate, J-domain co-chaperones tend to dis-
sociate from the product of the Hsp70-mediated ATP-fueled
unfolding reaction (60); with the co-chaperones preferentially
binding the composite trans-assembled structures, the unfold-
ing action of substrate-bound Hsp70 (41) would result in the
progressive destruction of the co-chaperone-binding sites on
substrate.
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